NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.

The financing will be used to support product development and clinical trials.

Originate Ventures led the round, which also included investors Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. With recent funding from the National Institutes of Health, new funds total $2.5 million, the Bethlehem, Penn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.